Zydus, a leading discovery-based, global pharmaceutical company, has informed exchanges that the company has completed its Phase II(a) clinical study of NLRP3 inhibitor ‘Usnoflast (ZYIL1)’ in patients with Amyotrophic Lateral Sclerosis (ALS).
In the exchange filing, the company shared, “ALS patients experience neuroinflammation and rapid neurodegeneration. Axonal neurodegeneration leads to formation of neurofilaments which first accumulate in CSF of ALS patients, and then slowly these neurofilaments enter blood circulation. Owing to rapid neurodegeneration, steady loss of the ability to move,speak, eat, eventually breathe, paralysis and death have been reported in ALS patients.”
ALS affects roughly 32,000 people in the United States, with 5,000 new patients diagnosed each year, according to Centers for Disease Control and Prevention (CDC) statistics. It is estimated that about 30,000 people across Europe (the United Kingdom and the European Union) and over 75,000 people in India are affected with ALS. People with ALS live an average of two to five years after diagnosis, with respiratory failure causing the majority of deaths.
